Intra-Cellular Therapies Aktie
120,00
EUR
-2,00
EUR
-1,64
%
Werbung
Intra-Cellular Therapies Aktie Analyse
| 08.02.18 | Intra-Cellular Therapies Outperform | RBC Capital Markets | |
| 15.12.17 | Intra-Cellular Therapies Buy | Canaccord Adams | |
| 16.12.16 | Intra-Cellular Therapies Overweight | Cantor Fitzgerald | |
| 29.09.16 | Intra-Cellular Therapies Neutral | SunTrust | |
| 29.09.16 | Intra-Cellular Therapies Outperform | RBC Capital Markets | |
| 17.09.15 | Intra-Cellular Therapies Outperform | RBC Capital Markets | |
| 14.04.15 | Intra-Cellular Therapies Outperform | RBC Capital Markets |
Werbung
Werbung